Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Mar 1, 2023
Date Accepted: Aug 10, 2023

The final, peer-reviewed published version of this preprint can be found here:

Content and Quality of Mobile Apps for the Monitoring of Musculoskeletal or Neuropathic Pain in Australia: Systematic Evaluation

Simmich J, Ross MH, Andrews NE, Vaezipour A, Russell TG

Content and Quality of Mobile Apps for the Monitoring of Musculoskeletal or Neuropathic Pain in Australia: Systematic Evaluation

JMIR Mhealth Uhealth 2023;11:e46881

DOI: 10.2196/46881

PMID: 37706480

PMCID: 10510453

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

A systematic evaluation of mobile apps for the monitoring of pain: Review of content and quality

  • Joshua Simmich; 
  • Megan H Ross; 
  • Nicole Emma Andrews; 
  • Atiyeh Vaezipour; 
  • Trevor Glen Russell

ABSTRACT

Background:

Mobile applications (apps) offer a potential mechanism for clinicians to monitor pain levels conveniently and remotely in people with chronic pain within their own environment. However, the quality of currently available applications and the usefulness of included features from a clinical perspective is not known.

Objective:

The aim of the study is to appraise the quality of currently available smartphone apps designed for monitoring the intensity or presence of musculoskeletal or neuropathic pain.

Methods:

A systematic search was performed in the Australian Apple and Google Play stores. Apps were included if they were designed to monitor the intensity or presence of musculoskeletal or neuropathic pain and were available in the English language in the Australian app stores. Data pertaining to the intended use of the app and clinical population were extracted using a custom designed data extraction form and app quality was assessed using the 23-item Mobile Apps Rating Scale.

Results:

Of the 2190 apps screened, 49 met inclusion criteria. Apps were primarily designed for adult users (>73%) with non-specific musculoskeletal or neuropathic pain conditions, arthritis and joint pain (~90%). All apps monitored pain intensity, with almost half also specifying pain location. Overall, the mean quality scores using the Mobile Apps Rating Scale ranged from 1.5 to 4.4 (out of 5.0). Between 20-22% of apps involved clinicians and/or consumers in their development and 20% had published literature relating to the development or use of the app in clinical scenarios. While 71% had data sharing features, only 5 apps enabled client-clinician communication through the app.

Conclusions:

The overall quality of mobile apps currently available for monitoring pain intensity is adequate. Presently, mobile applications for remote pain monitoring lack functionality for clinicians to view data between consults. Both users and clinicians should be aware of limitations of these apps, and make informed choices in using or recommending apps that best suit the clinical need.


 Citation

Please cite as:

Simmich J, Ross MH, Andrews NE, Vaezipour A, Russell TG

Content and Quality of Mobile Apps for the Monitoring of Musculoskeletal or Neuropathic Pain in Australia: Systematic Evaluation

JMIR Mhealth Uhealth 2023;11:e46881

DOI: 10.2196/46881

PMID: 37706480

PMCID: 10510453

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.